UK Market Exodus: Companies that moved away from London listing in recent years
UK Market Exodus: Companies that moved away from London listing in recent years Updates October 1, 2025 story to add Flutter and Magnum items
June 12 (Reuters) - FanDuel owner Flutter Entertainment FLTRF.L will delist from the London Stock Exchange in August, the company said on Friday, in the latest blow for the bourse.
A growing number of companies have either shelved plans to list in London, exited the market altogether, or aimed to better capitalise on stronger foreign markets by demoting their London listing and upgrading their listings elsewhere.
This trend is largely driven by investor pushback and post-Brexit-related challenges that have pressured UK market valuations.
2026
Flutter Entertainment FLTRF.L: The betting giant said in June it would delist from the London Stock Exchange in August, while retaining its primary NYSE listing.
The company, which has a valuation of £14.34 billion ($19.23 billion), said the decision was in the best interest of its shareholders. The FanDuel owner had moved its primary listing to the NYSE in 2024.
2025
ASTRAZENECA AZN.L: While the pharma giant and one of London's most valuable companies had said in September it was not exiting London, it did lay out plans to switch to a direct listing of its shares in the U.S.
The company has a valuation of £173.21 billion, and many industry experts have warned that its move could prompt other large companies to follow suit.
PETERSHILL PARTNERS PHLL.L: The British investment group had said in September it would delist from the London Stock Exchange and return money to shareholders, citing dissatisfaction with its share price performance and valuation.
The company is valued at £3.32 billion
WISE PLC WISEa.L: The British fintech received shareholder approval on July 28 to shift its primary stock market listing from the LSE to the U.S.
The company, valued at £10.60 billion, said the move is aimed at improving access to capital and boosting its profile among global investors while still maintaining a secondary listing in London.
COBALT: The Glencore-backed metals investor scrapped its plans for a London IPO IPO-COBL.L on June 4, which, according to one source, was driven by a lack of demand.
The company, valued at around $230 million, would have seen London's largest market debut since Air Astana's AIRA.KZ listing in February 2024.
INDIVIOR INDV.L: The drugmaker in early June said it will cancel its secondary listing on the LSE effective July 25, citing cost savings and a desire to align more closely with its U.S.-focused operations.
Magnum Ice Cream MICCT.AS: The ice cream maker, which was spun off from Unilever ULVR.L, debuted on the Amsterdam exchange as its primary listing with a valuation of about €7.8 billion.
The company also has secondary listings in London and New York.
SHEIN: The online fast-fashion retailer is working towards a listing in Hong Kong after its proposed IPO in London failed to secure the green light from Chinese regulators, three sources with knowledge of the matter told Reuters in May.
However, before its attempt to list in London, Shein had pursued a listing in New York, as part of its efforts to gain legitimacy as a global, rather than a Chinese company, and to access a wide pool of large Western investors.
2024
JUST EAT TAKEAWAY TKWY.AS: The Amsterdam-listed food delivery company delisted from the LSE in December, citing efforts to reduce administrative and regulatory costs.
The company has a market value of €4.03 billion.
ASHTEAD AHT.L: The second-largest equipment rental company in the U.S. said in December it plans to shift its listing to New York.
With a market value of 20.95 billion pounds, Ashtead has been listed in London since 1986, and transformed into a major U.S. player in the early 2000s.
WOODSIDE ENERGY WDS.AX: The oil and gas giant, in October 2024, decided to delist from the LSE to reduce its administrative costs.
UNISYS UIS.N: The IT consulting firm announced its intention to cancel its standard listing on the LSE, citing low trading volume of its common stock in October 2024.
TUI TUI1n.DE: Shareholders of Europe's largest travel operator voted in February 2024 to remove the firm from LSE saying a single German listing will better reflect its ownership and trading patterns in February 2024.
The Hanover-headquartered company has a market value of €3.93 billion.
2023
MARSH & MCLENNAN MMC.N: The insurance broker giant, valued at $99.08 billion, announced its intention to delist from the LSE, citing low trading volume in November 2023, with its primary listing remaining on the NYSE.
KINGSPAN KSP.I: The Irish construction company, valued at €12.79 billion, delisted from the LSE in 2023, citing negligible trading in its shares in London and maintaining its primary listing in Dublin.
CRH CRH.N: The building materials solutions provider, which has $80.44 billion in market value, switched its primary listing to the NYSE in 2023, while maintaining a standard listing on the LSE.
ARM HOLDINGS: The UK-based chip designer chose Nasdaq ARM.O over London for its 2023 IPO — the largest of that year.
The company, valued at $149.88 billion, was listed in London for 18 years until 2016, when it was taken private by SoftBank 9984.T in a $32 billion acquisition.
2022
FERGUSON: North America-focused plumbing and HVAC products supplier shifted its primary listing to New York in 2022.
2021
BHP: The world's largest miner by market value made Australia BHP.AX its primary stock market when it ended its dual-listing structure in 2021. The company was the second largest by market value in London when it left the stock market.
($1 = 0.8500 euros)
($1 = 0.7459 pounds)
(Reporting by Raechel Thankam Job, DhanushVignesh Babu, Nithyashree R B, and Pushkala Aripaka in Bengaluru; Editing by Mrigank Dhaniwala, Shilpi Majumdar and Subhranshu Sahu)
Recent news on AstraZeneca
See all newsUK Market Exodus: Companies that moved away from London listing in recent years
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (updated)
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal